5.4.3.8	4,5-Dioxovalerate	competitive inhibition of pyridoxamine-phosphate form of the enzyme and mixed-type inhibition of the pyridoxal-phosphate form of the enzyme	12361	
5.4.3.8	4-Amino-5-fluoro-pentanoic acid	-	91631	
5.4.3.8	4-Amino-5-hexenoic acid	-	91632	
5.4.3.8	4-Amino-5-hexynoic acid	-	43409	
5.4.3.8	Aminooxyacetate	20 mM, 57% inhibition	1374	
5.4.3.8	Aminooxyacetate	-	1374	
5.4.3.8	cycloserine	20 mM, 43% inhibition	2837	
5.4.3.8	D-penicillamine	20 mM, 9% inhibition	2733	
5.4.3.8	gabaculine	0.005 mM, 83% inhibition. Irreversible inhibition which requires the presence of either glutamate-1-semialdehyde or 5-amino-4-oxopentanoate	1869	
5.4.3.8	gabaculine	complete inactivation by gabaculine when the enzyme is exposed to 5-amino-4-oxopentanoate, levulinate or 4,5-dioxovalerate in absence of glutamate 1-semialdehyde	1869	
5.4.3.8	gabaculine	0.0005 mM, 50% inhibition. The inhibition is reversible up to 1 h after its addition, if the gabaculine is removed by gel filtration, before the enzyme is incubated by gel filtration, before the enzyme is incubated with substrate. Irreversible inhibition is obtained by preincubation of the enzyme at 30°C either for several hours with gabaculine alone or for a few min with both gabaculine and glutamate-1-semialdehyde	1869	
5.4.3.8	gabaculine	-	1869	
5.4.3.8	gabaculine	wild-type enzyme is inhibited, gabaculine-resistant mutant enzyme is not inhibited	1869	
5.4.3.8	gabaculine	potent inhibitor	1869	
5.4.3.8	glyoxylate	20 mM, 27% inhibition	101	
5.4.3.8	additional information	no inhibition by 3-hydroxyglutamate	2	
5.4.3.8	additional information	5 mM EDTA has no effect on activity	2	
5.4.3.8	p-chloromercuribenzoate	0.1 mM, 45% inhibition	43	
5.4.3.8	pyridoxal 5'-phosphate	5 mM, 47% inhibition	32	
5.4.3.8	pyridoxal 5'-phosphate	-	32